Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

Abstract This single-arm phase II study investigated the efficacy and safety of cabozantinib combined with nivolumab in metastatic triple-negative breast cancer (mTNBC). The primary endpoint was objective response rate (ORR) by RECIST 1.1. Biopsies at baseline and after cycle 1 were analyzed for tum...

Full description

Bibliographic Details
Main Authors: Romualdo Barroso-Sousa, Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson III, Deborah Dillon, Zohreh Amoozgar, Beth Overmoyer, Stuart J. Schnitt, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer Van Allen, Dan G. Duda, Sara M. Tolaney
Format: Article
Language:English
Published: Nature Portfolio 2021-08-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00287-9

Internet

https://doi.org/10.1038/s41523-021-00287-9

Similar Items